Status:

TERMINATED

Neurovegetative Decoupling in Somatoform Disorders : Biofeedback Interest

Lead Sponsor:

University Hospital, Grenoble

Collaborating Sponsors:

Laboratoire de Psychologie et NeuroCognition

Laboratoire interuniversitaire de psychologie - LIP-PC2S

Conditions:

Somatoform Disorders

Irritable Bowel Syndrome

Eligibility:

All Genders

18-70 years

Phase:

NA

Brief Summary

Evaluation of the physiological and clinical effects of the biofeedback training with patients suffering from somatoform disorders, depending on their neurovegetative profile related to a visceral-bra...

Detailed Description

Somatoform disorders \[SD\] are defined as physiological function or organ disturbances unexplained by a specific diagnosis criterion. Some approaches have recently defended the idea of common factors...

Eligibility Criteria

Inclusion

  • Somatoform disorders (IBS or PNES) diagnosis must be established by the partner doctors
  • Participants must have home computer
  • Participants must be of the age of majority
  • Participants must be registered for social security
  • Participants must have signed an informed consent

Exclusion

  • Specially protected participants (under clauses L1121-5 and L1121-8 by the code of public health): juveniles, pregnant womens, nursing mothers, law's protection peoples
  • Participants suffering from a severe psychiatric disease needing specialised attention
  • Participants suffering from or have suffered from a severe disease causing autonomic dysfunctions (heart failure, asthma, blood disease, renal failure, peripheral neuropathy, vagotomy, thyroid disorder, alcoholism, liver disease, amyloidosis)
  • Participants taking medication which could be impact autonomic nervous system activity (anticholinergic, antiarrhythmics, clonidine, beta-blockers, tricyclic anti-depressants, metronidazole)
  • Participants placing under judicial or administrative supervisions
  • Participants were compensated more than 4500 euros because of his research protocol participation concerning human over the 12 months prior to the actual study
  • Participants being not be able to contact in emergency
  • Participants being in an exclusion period from another study

Key Trial Info

Start Date :

March 16 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 5 2023

Estimated Enrollment :

46 Patients enrolled

Trial Details

Trial ID

NCT04807933

Start Date

March 16 2021

End Date

September 5 2023

Last Update

December 10 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Hospital, Grenoble Alpes

Grenoble, Isère, France, 38700